Results 21 to 30 of about 2,242,189 (260)
Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells [PDF]
BMC Cancer, 2021 Abstract Background The mechanisms of endocrine resistance are complex, and deregulation of several oncogenic signalling pathways has been proposed. We aimed to investigate the role of the EGFR and Src-mediated STAT3 signalling pathway in tamoxifen-resistant breast cancer cells. Methods
Seo Yun Moon +9 more
openaire +3 more sources
Cancer Medicine, 2020 Tamoxifen‐based hormone therapy is central for the treatment of estrogen receptor positive (ER+) breast cancer. However, the acquired tamoxifen resistance, typically co‐exists with hypoxia, remains a major challenge.
Ying Li +10 more
doaj +1 more source
Molecular Analysis of Acquired Tamoxifen Resistance in Breast Cancer Cell Line
Asian Pacific Journal of Cancer Biology, 2017 Background: Tamoxifen is an FDA approved drug for the prevention and the treatment of breast cancer, but its therapeutic benefit is limited by the development of drug resistance.
Mansour Abachi +4 more
doaj +3 more sources
miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22
Cellular Physiology and Biochemistry, 2018 Background/Aims: Most of estrogen receptor positive breast cancer patients respond well initially to endocrine therapies, but often develop resistance during treatment with selective estrogen receptor modulators (SERMs) such as tamoxifen.
Jun Li +5 more
doaj +1 more source
Scientific Reports, 2020 Tamoxifen resistance is emerging as a big challenge in endocrine therapy of luminal A breast cancer patients. In this study, we aimed to determine the molecular changes of PI3K/AKT/PTEN signaling pathway during tamoxifen-resistance development using ...
Lama Hamadneh +3 more
doaj +1 more source
Tamoxifen Resistance: Emerging Molecular Targets [PDF]
International Journal of Molecular Sciences, 2016 17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a result, blockade of the E2 signal through either tamoxifen (TAM) or aromatase inhibitors is an important therapeutic strategy to treat or prevent estrogen receptor (ER) positive breast cancer.
Milena Rondón-Lagos +4 more
openaire +2 more sources
EBioMedicine, 2020 Background: Prioritization of breast cancer patients based on the risk of resistance to tamoxifen plays a significant role in personalized therapeutic planning and improving disease course and outcomes. Methods: In this work, we demonstrate that a genome-
Sarra M. Rahem +3 more
doaj +1 more source
Cholesterol metabolism and resistance to tamoxifen
Current Opinion in Pharmacology, 2012 The oncoprotein MUC-1 was shown to upregulate the transcription of genes encoding cholesterol and lipid metabolic enzymes and correlated with a resistance to Tamoxifen (Tam) despite the presence of estrogen receptor α in breast cancer tumors. The importance of this observation is supported by molecular studies on Tam suggesting two additional ...
Poirot, Marc +2 more
openaire +2 more sources
Journal of Genetic Engineering and Biotechnology, 2022 Background Tamoxifen resistance in estrogen receptor positive (ER+) breast cancer therapy increases, which is the leading cause of cancer treatment failure, as it can impair patients’ prognoses, cause cancer recurrence, metastasis, and death. Combination
Wilfan Ibadurrahman +2 more
doaj +1 more source
Hepatology, EarlyView., 2022 Abstract Background and Aims Peroxisome proliferator‐activated receptor α (PPARα) regulates fatty acid transport and catabolism in liver. However, the role of intestinal PPARα in lipid homeostasis is largely unknown. Here, intestinal PPARα was examined for its modulation of obesity and NASH. Approach and Results Intestinal PPARα was activated and fatty
Tingting Yan +22 more
wiley +1 more source